A Single-Center, Clinical Study to Evaluate the Safety of a New Personal Lubricant in Healthy Female Subjects
Primary Purpose
Erythema, Edema
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Trojan "Chameleon" Personal Lubricant
Sponsored by
About this trial
This is an interventional other trial for Erythema
Eligibility Criteria
Inclusion Criteria:
- no participation in a similar study 2-weeks prior
- may be post-menopausal or have had a hysterectomy
- if sexually active, and of child bearing potential, subjects using adequate non-barrier method of birth control
- free from any vaginal disorders
- sexually active and monogamous, heterosexual relationship, and whose male partner is willing and able to give informed consent and agrees to engage in sexual intercourse at least twice each week during the two-week study or is not sexually active
- personal lubricant user and agrees to replace her usual personal lubricant with the investigational product
- can start regardless of where they are in their cycles
- agrees to use the provided investigational product at least four times weekly over the two week study period
- exhibits no clinically significant evidence of vulvar or vaginal irritation, as determined by a study doctor, and no reports of sensory irritation at the baseline exam
- willing to refrain from introducing any new vaginal products, or using vaginal medications or local contraceptives during study
- agrees to refrain from douching or using any medications, powder, lotions or personal care products in the vulvar or perianal area
- willing to use a urine pregnancy test provided to them at baseline and on third visit
- standard medical history form on file
- signed informed consent
- completed HIPAA
- dependable and able to follow directions as outlined
- receives a score of 0 or 0.5 for erythema and edema: and 0 for sensorial irritation (burning, stinging, itching and dryness) during the first examination.
Exclusion Criteria:
- pregnant, nursing or planning a pregnancy
- currently using or has used within two weeks prior to the study initiation, any systemic or topical corticosteroids, vasoconstrictors, antibiotics, anti-inflammatories or antihistamines
- known allergies to vaginal or any cosmetic products
- reports history of recurrent bladder, vaginal infections or incontinence
- exhibits or reports gynecologic abnormalities or has had vaginitis within 60 days prior to study initiation
- uses a vaginal ring, diaphram or cervical/vault caps, condoms, or condoms with spermicide as a means of contraception
- participated in a study involving the vaginal area or in an investigational systemic drug study within two weeks of study initiation
- receives a score higher than 0/5 for erythema, edema or >0 for burning, stinging, or itching, during first examination or shows any other sign of mucosal irregularities
Sites / Locations
- Clinical Research Laboratories, LLC
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Healthy subject
Arm Description
Healthy subject exposed to Trojan "Chameleon" Personal Lubricant at least four times weekly for two weeks
Outcomes
Primary Outcome Measures
Number of Subjects With Observed Local Erythema Based on the 5 Point Scoring Scale
Number of subjects with observed local erythema by obstetrician/gynecologist examination as graded on 5 point clinical scale: 0 = normal appearance no irritation, 0.5 = slight, irregular erythema, 1 = mild erythema, 2 = moderate erythema 3 = severe erythema
Number of Subjects With Observed Edema Based on the 5 Point Scoring Scale
Number of subjects with observed local edema by obstetrician/gynecologist examination as graded on 5 point clinical scale: 0 = normal appearance no edema, 0.5 = slight edema, 1 = mild edema, 2 = moderate edema 3 = severe edema
Secondary Outcome Measures
Full Information
NCT ID
NCT02737852
First Posted
April 11, 2016
Last Updated
August 2, 2017
Sponsor
Church & Dwight Company, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT02737852
Brief Title
A Single-Center, Clinical Study to Evaluate the Safety of a New Personal Lubricant in Healthy Female Subjects
Study Type
Interventional
2. Study Status
Record Verification Date
August 2017
Overall Recruitment Status
Completed
Study Start Date
March 2016 (undefined)
Primary Completion Date
May 2016 (Actual)
Study Completion Date
May 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Church & Dwight Company, Inc.
4. Oversight
5. Study Description
Brief Summary
To evaluate the safety of a new personal lubricant when used at least four times weekly for two weeks (including at least twice weekly during sexual intercourse for subjects with monogamous male partners), in a population consisting of healthy females.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Erythema, Edema
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Masking Description
The new personal lubricant was used by all participants
Allocation
N/A
Enrollment
32 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Healthy subject
Arm Type
Experimental
Arm Description
Healthy subject exposed to Trojan "Chameleon" Personal Lubricant at least four times weekly for two weeks
Intervention Type
Device
Intervention Name(s)
Trojan "Chameleon" Personal Lubricant
Intervention Description
silicone base with sensate
Primary Outcome Measure Information:
Title
Number of Subjects With Observed Local Erythema Based on the 5 Point Scoring Scale
Description
Number of subjects with observed local erythema by obstetrician/gynecologist examination as graded on 5 point clinical scale: 0 = normal appearance no irritation, 0.5 = slight, irregular erythema, 1 = mild erythema, 2 = moderate erythema 3 = severe erythema
Time Frame
2 weeks
Title
Number of Subjects With Observed Edema Based on the 5 Point Scoring Scale
Description
Number of subjects with observed local edema by obstetrician/gynecologist examination as graded on 5 point clinical scale: 0 = normal appearance no edema, 0.5 = slight edema, 1 = mild edema, 2 = moderate edema 3 = severe edema
Time Frame
2 weeks
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
no participation in a similar study 2-weeks prior
may be post-menopausal or have had a hysterectomy
if sexually active, and of child bearing potential, subjects using adequate non-barrier method of birth control
free from any vaginal disorders
sexually active and monogamous, heterosexual relationship, and whose male partner is willing and able to give informed consent and agrees to engage in sexual intercourse at least twice each week during the two-week study or is not sexually active
personal lubricant user and agrees to replace her usual personal lubricant with the investigational product
can start regardless of where they are in their cycles
agrees to use the provided investigational product at least four times weekly over the two week study period
exhibits no clinically significant evidence of vulvar or vaginal irritation, as determined by a study doctor, and no reports of sensory irritation at the baseline exam
willing to refrain from introducing any new vaginal products, or using vaginal medications or local contraceptives during study
agrees to refrain from douching or using any medications, powder, lotions or personal care products in the vulvar or perianal area
willing to use a urine pregnancy test provided to them at baseline and on third visit
standard medical history form on file
signed informed consent
completed HIPAA
dependable and able to follow directions as outlined
receives a score of 0 or 0.5 for erythema and edema: and 0 for sensorial irritation (burning, stinging, itching and dryness) during the first examination.
Exclusion Criteria:
pregnant, nursing or planning a pregnancy
currently using or has used within two weeks prior to the study initiation, any systemic or topical corticosteroids, vasoconstrictors, antibiotics, anti-inflammatories or antihistamines
known allergies to vaginal or any cosmetic products
reports history of recurrent bladder, vaginal infections or incontinence
exhibits or reports gynecologic abnormalities or has had vaginitis within 60 days prior to study initiation
uses a vaginal ring, diaphram or cervical/vault caps, condoms, or condoms with spermicide as a means of contraception
participated in a study involving the vaginal area or in an investigational systemic drug study within two weeks of study initiation
receives a score higher than 0/5 for erythema, edema or >0 for burning, stinging, or itching, during first examination or shows any other sign of mucosal irregularities
Facility Information:
Facility Name
Clinical Research Laboratories, LLC
City
Piscataway
State/Province
New Jersey
ZIP/Postal Code
08854
Country
United States
12. IPD Sharing Statement
Learn more about this trial
A Single-Center, Clinical Study to Evaluate the Safety of a New Personal Lubricant in Healthy Female Subjects
We'll reach out to this number within 24 hrs